Bamco Inc. NY Sells 558,597 Shares of Tempus AI, Inc. (NASDAQ:TEM)

Bamco Inc. NY decreased its holdings in Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 71.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 225,800 shares of the company's stock after selling 558,597 shares during the quarter. Bamco Inc. NY owned 0.15% of Tempus AI worth $12,780,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in TEM. First Horizon Advisors Inc. bought a new position in Tempus AI during the 3rd quarter valued at about $30,000. Vestor Capital LLC acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $153,000. The Manufacturers Life Insurance Company grew its position in Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company's stock worth $1,686,000 after acquiring an additional 2,765 shares during the last quarter. Sandia Investment Management LP acquired a new stake in Tempus AI during the 2nd quarter valued at $136,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Tempus AI in the 3rd quarter valued at $258,000.

Tempus AI Stock Down 6.5 %

NASDAQ:TEM traded down $4.11 on Tuesday, reaching $58.83. The company's stock had a trading volume of 555,696 shares, compared to its average volume of 1,183,974. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock's 50-day moving average price is $53.31. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Wall Street Analyst Weigh In

TEM has been the subject of a number of recent research reports. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and boosted their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America downgraded shares of Tempus AI from a "buy" rating to a "neutral" rating and upped their target price for the company from $45.00 to $60.00 in a research report on Wednesday, October 2nd. Loop Capital lifted their price target on shares of Tempus AI from $48.00 to $57.00 and gave the stock a "buy" rating in a research report on Tuesday, October 15th. Piper Sandler restated a "neutral" rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Tempus AI from $42.00 to $47.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $54.22.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.